Encodia

Market position

Encodia was one of several entrants attempting to build "next-generation" protein analysis tools, explicitly aspiring, in its CTO's words, to be to proteomics what Illumina was to genomics. It positioned its NGS-readout approach against the incumbent mass spectrometry workflows that dominate proteomics and against antibody-based tools, some of which also couple to DNA and NGS readouts. Trade press framed the company as a candidate to become a dominant proteomics platform provider, a thesis that was not realized given the 2025 shutdown.

The principal differentiator was reverse-translating peptide information into DNA-barcoded libraries so amino acid identities could be read on existing NGS instruments, rather than by mass spectrometry or single-molecule fluorescence, allowing the company to benefit from ongoing declines in sequencing cost and increases in sequencer throughput. Secondary differentiators cited were benchtop accessibility for non-specialist labs and native compatibility with multiomic and proteo-genomic data integration.

Technology

ProteoCode is a patented protein analysis technology that tags peptides with DNA barcodes, effectively reverse-translating protein sequence information into a DNA code that can be read out using standard next-generation sequencing workflows. The approach was designed to be massively parallel and to generate an NGS data type familiar to researchers already performing genomics and transcriptomics, enabling proteo-genomic and multiomic data integration. Initial capability targeted linear protein sequence determination, mapping, and quantification, with post-translational modifications and proteoform analysis planned as later development. The technology was intended to be delivered via an accessible benchtop instrument.

Go-to-market

The stated approach was to lower the barrier for researchers who use NGS but avoid proteomics because it requires collaboration with a mass spectrometry lab, by supplying benchtop instruments and reagents that produce NGS-compatible data on the sequencers labs already own. Sources do not describe specific sales channels, distribution partners, or commercial launch details.

Academic and translational researchers already conducting genomics and transcriptomics work, pharmaceutical and biotechnology companies, and clinical research laboratories requiring higher-throughput protein analysis for drug discovery and high-complexity diagnostics.

Geography

Headquartered in San Diego, California, United States. No other locations are documented in the sources.

History

Founded in 2015, Encodia operated in stealth mode from inception while developing its ProteoCode technology. Deerfield Management recorded an initial early-stage equity venture transaction with the company in December 2020, and Encodia closed a $75 million Series C in January 2021, with reporting attributing the round to investors including Northpond Ventures and Deerfield Management. One profile reports total venture funding of $79 million. The company later recruited Nigel Beard from Mission Bio as Chief Technology Officer. Encodia shut down in late 2025, filed an assignment for the benefit of creditors in California on November 7, 2025, and was reported by GenomeWeb in January 2026 to have ceased operations and to be auctioning off laboratory equipment.

Risks & controversies

The company ultimately failed: it shut down in late 2025 and made an assignment for the benefit of creditors filing with the state of California on November 7, 2025, a process similar to a bankruptcy proceeding, and by January 2026 was auctioning laboratory equipment including mass spectrometers, sequencers, and liquid handlers. The number of employees affected was not disclosed and company officials did not respond to press inquiries. Strategically, the business was explicitly dependent on the trajectory of third-party NGS technology and on continued declines in sequencing cost. Source data on the company is also inconsistent — one aggregator profile lists an employee band of 1,001-5,000 alongside a headcount figure of about 47, and states the founding year and founders are undisclosed while trade press names them.